Cargando…
Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?
In recent decades, very few new psychiatric drugs have entered the market. Thus, improvement in the use of antidepressant and antipsychotic therapy has to focus mainly on enhanced and more personalized treatment with the currently available drugs. One important aspect of such individualization is em...
Autores principales: | van Westrhenen, Roos, Aitchison, Katherine J., Ingelman-Sundberg, Magnus, Jukić, Marin M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080976/ https://www.ncbi.nlm.nih.gov/pubmed/32226396 http://dx.doi.org/10.3389/fpsyt.2020.00094 |
Ejemplares similares
-
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
por: Turnbull, Samantha, et al.
Publicado: (2015) -
OBHDP Editorial: Where we are, how we got here, and where we’re going
por: Kouchaki, Maryam
Publicado: (2020) -
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?
por: Ngan, Nguyen Thi Thuy, et al.
Publicado: (2022) -
Dietary Supplement for Core Symptoms of Autism Spectrum Disorder: Where Are We Now and Where Should We Go?
por: Li, Yong-Jiang, et al.
Publicado: (2017) -
Editorial: From Trial and Error to Individualised Pharmacogenomics-Based Pharmacotherapy in Psychiatry
por: van Westrhenen, R., et al.
Publicado: (2021)